UFP Technologies reported third-quarter sales of $172.4 million, reflecting an 11.6% increase compared to the previous year, according to the company’s earnings call on November 4, 2026. The firm noted organic sales growth, which excludes revenue from acquisitions, was recorded at 11.1% for the period.
Chief Executive Officer Mitchell Rock highlighted that medical technology sales grew by 12.5% during the quarter. The growth is attributed to diverse demand across its product lines, such as cardiovascular, orthopedic, infection control, and patient-handling items, rather than reliance on a single customer or contract. “One of the real strengths of UFP is that our growth does not depend on any single customer, program or end market,” Rock stated.
However, challenges were noted regarding the company’s plans to move its labor-intensive medical product assembly business, AJR, to the Dominican Republic. This transition is aimed at reducing expenses but has faced delays due to customer qualification requirements, which have temporarily impacted gross margins. Senior Vice President Ronald Lataille acknowledged this challenge: “This improvement was despite continued margin headwind at AJR as high labor products scheduled to be transferred to the Dominican Republic continues to be contingent on customer qualification.”
Despite these hurdles, UFP Technologies maintains a strong financial position. The company concluded the quarter with a leverage ratio under 1x, indicating low debt relative to earnings. Management is expanding its credit facility to facilitate larger acquisitions and fund internal growth initiatives. Rock remarked on this strategic direction, indicating a commitment to pursuing larger businesses while investing in organic growth.
Looking ahead, UFP Technologies plans to leverage new manufacturing capacity becoming operational in the Dominican Republic and capitalize on recent niche acquisitions to enhance its specialized printing and molding capabilities. Rock emphasized the firm’s strengths in customer relationships and expanding operational capabilities: “We have strong customer relationships, expanding capabilities, new capacity coming online, meaningful organic growth opportunities, and an active acquisition pipeline.”
The company aims to focus on the production of single-use medical components while balancing capital allocation for acquisitions. Rock concluded by reiterating the firm’s strategy to grow alongside its customers, improve operations, and create long-term value for shareholders. The outlook for operational momentum remains positive as UFP Technologies approaches 2027.
